Table 2.
Viability analysis of cancer cells treated with a chemotherapeutic. The assay was performed using the Muse Annexin V and Dead Cell Assay Kit. The data were collected from at least three independent experiments. The representative assay results are graphically presented in Figure 5. p-value < 0.05 (*), 0.01 (**), 0.001 (***), or not significant (ns).
| Cell Line | Chemotherapeutic Drug [µM] | HtrA4 Variant | Live Cells [%±SD] | Early Apoptotic Cells [%±SD] | Late Apoptotic/Dead Cells [%±SD] | Total Apoptotic Cells | ||
|---|---|---|---|---|---|---|---|---|
| [%] | Statistical Analysis | |||||||
| A549 | Etoposide | 0 | − HtrA4 | 80.6 ± 4.7 | 12.9 ± 3.1 | 6.4 ± 0.8 | 19.3 | ns |
| + HtrA4 | 80.9 ± 0.8 | 13.4 ± 3.0 | 5.3 ± 1.1 | 18.7 | ||||
| 15 | − HtrA4 | 39.0 ± 1.5 | 46.5 ± 3.7 | 12.7 ± 0.3 | 59.2 | * | ||
| + HtrA4 | 29.4 ± 2.1 | 55.4 ± 4.3 | 14.4 ± 3.4 | 69.7 | ||||
| 0 | − ∆N-HtrA4 | 80.5 ± 2.3 | 10.7 ± 2.3 | 8.4 ± 0.9 | 19 | ns | ||
| + ∆N-HtrA4 | 77.0 ± 5.1 | 12.2 ± 0.7 | 10.1 ± 1.4 | 22.4 | ||||
| 15 | − ∆N-HtrA4 | 37.9 ± 2.8 | 47.8 ± 3.5 | 13.0 ± 1.5 | 60.8 | ** | ||
| + ∆N-HtrA4 | 26.7 ± 2.6 | 57.5 ± 1.1 | 15.3 ± 2.1 | 72.8 | ||||
| A549 | Etoposide | 0 | control | 86.8 ± 0.9 | 5.9 ± 0.9 | 6.7 ± 1.2 | 12.6 | ns |
| shHtrA4 | 85.1 ± 5.8 | 8.2 ± 2.3 | 6.4 ± 1.1 | 14.7 | ||||
| 7.5 | control | 61.6 ± 7.1 | 26.65 ± 3.0 | 10.7 ± 0.5 | 37.3 | ns | ||
| shHtrA4 | 67.9 ± 3.8 | 19.0 ± 0.1 | 11.4 ± 2.0 | 30.4 | ||||
| 15 | control | 51.8 ± 4.3 | 35.5 ± 1.3 | 11.8 ± 2.1 | 47.4 | ** | ||
| shHtrA4 | 63.9 ± 3.1 | 20.9 ± 1.4 | 13.7 ± 2.0 | 34.6 | ||||
| MCF7 | Cisplatin | 0 | control | 89.2 ± 4.2 | 3.3 ± 0.7 | 6.8 ± 0.2 | 10.1 | ns |
| shHtrA4 | 92.7 ± 2.5 | 2.8 ± 0.5 | 4.2 ± 0.4 | 7 | ||||
| 100 | control | 73.9 ± 2.1 | 4.8 ± 0.2 | 18.0 ± 1.8 | 22.8 | *** | ||
| shHtrA4 | 88.4 ± 2.3 | 4.0 ± 0.1 | 6.4 ± 0.5 | 10.3 | ||||
| 350 | control | 46.8 ± 5.4 | 16.8 ± 2.6 | 30.9 ± 3.2 | 47.7 | ** | ||
| shHtrA4 | 80.3 ± 7.3 | 6.3 ± 0.8 | 12.1 ± 1.5 | 18.4 | ||||